A New Treatment Option for Uncommon EGFR Mutations (BMIC-023)
Dr. Jack West reviews the new FDA approval for afatinib (Gilotrif) for specific uncommon EGFR mutations, including G719X, L861Q, and S768I, in advanced NSCLC. (6:35)
Tag Archives: T790M
Should Osimertinib Become First-Line Treatment of Choice for EGFR Mutation-Positive Advanced NSCLC, or Should it Be Saved for Later? (BMIC-017)
Dr. Jack West reviews the pros and cons of using osimertinib first line vs. “saving” it as a second line therapy, trying to determine the optimal sequence for EGFR-directed therapy in advanced EGFR mutation-positive NSCLC. (11:46)